CorMedix Inc
CRMD9.810USD
+0.160+1.66%
Close 11/28, 13:00（ET）Quotes delayed by 15 min
768.60MMarket Cap
4.73P/E TTM
More Details of CorMedix Inc Company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
CorMedix Inc Info
Ticker SymbolCRMD
Company nameCorMedix Inc
IPO dateMar 25, 2010
CEOMr. Joseph Todisco
Number of employees64
Security typeOrdinary Share
Fiscal year-endMar 25
Address300 Connell Drive
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code07922
Phone19085179500
Websitehttps://cormedix.com/
Ticker SymbolCRMD
IPO dateMar 25, 2010
CEOMr. Joseph Todisco
Company Executives of CorMedix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
--
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
--
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
-56.10%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
--
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
--
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
--
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
--
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
-56.10%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
39.74M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.40%
Abdalkader (Shaibatalhamd Aymen)
5.90%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
Deerfield Management Company, L.P.
4.22%
Other
74.05%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.40%
Abdalkader (Shaibatalhamd Aymen)
5.90%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
Deerfield Management Company, L.P.
4.22%
Other
74.05%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.96%
Investment Advisor/Hedge Fund
15.18%
Hedge Fund
11.14%
Individual Investor
7.05%
Research Firm
2.03%
Pension Fund
0.97%
Bank and Trust
0.33%
Insurance Company
0.03%
Venture Capital
0.03%
Other
37.28%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
313
36.30M
46.33%
+3.65M
2025Q2
280
26.40M
35.51%
-7.69M
2025Q1
281
29.73M
44.27%
-179.25K
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.80M
6.42%
+485.88K
+11.27%
Jun 30, 2025
Abdalkader (Shaibatalhamd Aymen)
4.65M
6.22%
+4.65M
--
Aug 08, 2025
The Vanguard Group, Inc.
4.31M
5.77%
+675.49K
+18.59%
Jun 30, 2025
Marshall Wace LLP
2.58M
3.46%
+2.35M
+1019.17%
Jun 30, 2025
State Street Investment Management (US)
1.60M
2.15%
+62.52K
+4.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.60M
2.14%
+163.40K
+11.40%
Jun 30, 2025
Citadel Advisors LLC
1.71M
2.3%
+1.61M
+1517.64%
Jun 30, 2025
Alyeska Investment Group, L.P.
750.00K
1%
+750.00K
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco Biotechnology & Genome ETF
2.22%
SPDR S&P Pharmaceuticals ETF
1.94%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.45%
VictoryShares Small Cap Free Cash Flow ETF
0.74%
First Trust Active Factor Small Cap ETF
0.35%
Janus Henderson Small Cap Growth Alpha ETF
0.26%
ALPS Barron's 400 ETF
0.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.22%
Vanguard US Multifactor ETF
0.18%
iShares Micro-Cap ETF
0.16%
View more
Invesco Biotechnology & Genome ETF
Proportion2.22%
SPDR S&P Pharmaceuticals ETF
Proportion1.94%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.45%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.74%
First Trust Active Factor Small Cap ETF
Proportion0.35%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0.26%
ALPS Barron's 400 ETF
Proportion0.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0.22%
Vanguard US Multifactor ETF
Proportion0.18%
iShares Micro-Cap ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CorMedix Inc?
The top five shareholders of CorMedix Inc are:
BlackRock Institutional Trust Company, N.A. holds 4.80M shares, accounting for 6.42% of the total shares.
Abdalkader (Shaibatalhamd Aymen) holds 4.65M shares, accounting for 6.22% of the total shares.
The Vanguard Group, Inc. holds 4.31M shares, accounting for 5.77% of the total shares.
Marshall Wace LLP holds 2.58M shares, accounting for 3.46% of the total shares.
State Street Investment Management (US) holds 1.60M shares, accounting for 2.15% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.80M shares, accounting for 6.42% of the total shares.
Abdalkader (Shaibatalhamd Aymen) holds 4.65M shares, accounting for 6.22% of the total shares.
The Vanguard Group, Inc. holds 4.31M shares, accounting for 5.77% of the total shares.
Marshall Wace LLP holds 2.58M shares, accounting for 3.46% of the total shares.
State Street Investment Management (US) holds 1.60M shares, accounting for 2.15% of the total shares.
What are the top three shareholder types of CorMedix Inc?
The top three shareholder types of CorMedix Inc are:
BlackRock Institutional Trust Company, N.A.
Abdalkader (Shaibatalhamd Aymen)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Abdalkader (Shaibatalhamd Aymen)
The Vanguard Group, Inc.
How many institutions hold shares of CorMedix Inc (CRMD)?
As of 2025Q3, 313 institutions hold shares of CorMedix Inc, with a combined market value of approximately 36.30M, accounting for 46.33% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 10.82%.
What is the biggest source of revenue for CorMedix Inc?
In FY2025Q2, the -- business generated the highest revenue for CorMedix Inc, amounting to -- and accounting for --% of total revenue.
